Latest Addiction Medicine News

A new study published in JAMA Network Open on May 7, 2026, engaged 42 national experts in hospital-based addiction treatment in a consensus-building process to develop best practices for hospital-initiated medications for opioid use disorder.

The Yale Department of Internal Medicine presented two staff members with the 2026 Department of Internal Medicine Service Excellence Award. Michelle Colon, senior administrative assistant, and June Weiss, research manager, both from the Section of General Internal Medicine, were presented with the awards at the Internal Medicine Staff Town Hall on April 21, 2026.

The College on Problems of Drug Dependence (CPDD) will present the James L. Sorensen Distinguished Treatment and Service Research Mentorship Award to David Fiellin, MD, professor of medicine (general medicine), of emergency medicine, and of public health, for his outstanding commitment to mentorship in treatment and service research.

The Yale Department of Internal Medicine announces its newest incoming class of residents for Match Day 2026.

The Department of Internal Medicine welcomes the following new faculty, staff, postgraduate associates, and postdoctoral associates and fellows who joined the team in February 2026.

Dr. Stephen Holt, Yale Medicine, addiction medicine physician and associate professor of medicine at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss alcohol consumption and what you need to know ahead of one of the biggest alcohol-facing holidays.

Yale School of Medicine's E. Jennifer Edelman, MD, MHS, tested an adaptive, team-based strategy to better integrate tobacco treatment into HIV clinics.

David Fiellin, MD, professor of medicine (general medicine), of emergency medicine, and of public health, and Sandra Gomez-Luna, MD, an assistant clinical professor in the Department of Psychiatry, were recently named Distinguished Fellows of the American Society of Addiction Medicine.

In a Yale study, researchers found that seven-day injectable buprenorphine and daily tablet buprenorphine are equally safe and effective in engaging patients with opioid use disorder in treatment after an emergency department visit.